MiNK Therapeutics (NASDAQ:INKT) reported its fourth-quarter and full-year 2025 financial results on Tuesday, detailing a well-capitalized path toward several major clinical readouts in the coming year.
The company, which specializes in invariant natural killer T (iNKT) cell therapies, ended the fiscal year with $13.4 million in cash and subsequently bolstered its balance sheet with an additional $3.0 million raised post-year-end.
For the full year 2025, MiNK reported a net loss of $12.5 million, reflecting a disciplined approach to research and development as it advances its allogeneic cell therapy platform.
A significant portion of the company’s current operational funding is derived from non-dilutive sources, including a $1.1 million C-Further collaboration, a prestigious NIH NIAID STTR grant, and the Mary Gooze award.
These funds are specifically earmarked to support new clinical starts scheduled for the first and second halves of 2026.
The company’s 2026 roadmap is centered on its lead programs in acute respiratory distress syndrome (ARDS) and graft-versus-host disease (GVHD).
MiNK is currently advancing Phase 2 trials in both indications, with management anticipating near-term data readouts that could validate the anti-inflammatory and tissue-remodeling properties of its iNKT cell candidates.
Strategically, MiNK is leveraging its "off-the-shelf" manufacturing capabilities to reduce the cost and complexity typically associated with cell therapies.
This scalability is a key component of its partnership strategy, as the company seeks to expand the application of its platform into broader inflammatory and autoimmune conditions beyond its initial oncology focus.
Management indicated that the current total capital of approximately $16.4 million provides a sufficient runway to reach the primary data catalysts in its Phase 2 programs.